What is an ominous sign of advanced SLE?

Choice A reason: Compartment syndrome involves increased pressure within a muscle compartment, causing pain, swelling, and neurovascular compromise. It typically presents with localized symptoms like severe pain and paresthesia, not systemic signs like tachycardia, pallor, or confusion. These findings in a humerus fracture suggest a broader complication, making this less likely.

Choice B reason: Deep vein thrombosis (DVT) causes localized swelling, pain, and redness, primarily in the lower limbs. Systemic symptoms like tachycardia or confusion are rare unless DVT progresses to pulmonary embolism. A humerus fracture is less associated with DVT, and the patient’s symptoms point to a more acute, systemic issue.

Choice C reason: Disseminated intravascular coagulopathy (DIC) involves widespread clotting and bleeding, often triggered by sepsis or trauma. While possible in severe trauma, it typically presents with bleeding or bruising, not primarily tachycardia, pallor, and confusion. These symptoms align more closely with fat embolism in the context of a long bone fracture.

Choice D reason: Fat embolism syndrome, common in long bone fractures like the humerus, occurs when fat globules enter the bloodstream, obstructing pulmonary or cerebral vessels. This causes tachycardia, pallor (from hypoxia), and confusion (from cerebral hypoxia). These systemic symptoms match the patient’s presentation, making fat embolism the most likely complication requiring urgent intervention.

Choice A reason: Zolpidem, a sedative-hypnotic, treats insomnia by enhancing GABA activity in the brain. It has no role in gout management, as it does not address uric acid levels, inflammation, or pain associated with gouty arthritis. Administering it would be irrelevant and fail to target the underlying pathophysiology of gout.

Choice B reason: Alprazolam, a benzodiazepine, manages anxiety by depressing central nervous system activity. It does not affect uric acid metabolism or inflammation in gout. Using it for gout is inappropriate, as it lacks anti-inflammatory or urate-lowering properties, offering no therapeutic benefit for the condition.

Choice C reason: Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production, preventing gout attacks. It is a first-line medication for chronic gout management, lowering serum urate levels to prevent crystal formation in joints. The nurse should prepare to administer it to address the client’s hyperuricemia effectively.

Choice D reason: Spironolactone, a potassium-sparing diuretic, treats hypertension and edema by antagonizing aldosterone. It has no direct effect on uric acid levels or gout inflammation. Its use could even increase uric acid reabsorption, potentially worsening gout, making it an inappropriate choice for this client.